Content about Pharmaceutics

September 23, 2010

Perrigo has filed for regulatory approval of a generic version of an over-the-counter medication for...

ALLEGAN, Mich. Perrigo has filed for regulatory approval of a generic version of an over-the-counter medication for frequent heartburn, prompting a lawsuit from the branded version’s manufacturer.

The company announced Friday that it had filed for approval for omeprazole and sodium bicarbonate in the 20 mg/1,100 mg strength. The medication is a generic version of Zegerid OTC, made by Schering-Plough HealthCare, a subsidiary of Merck.

 

September 23, 2010

Drug maker Warner Chilcott will buy the U.S. rights to a treatment for overactive bladder...

ARDEE, Ireland Drug maker Warner Chilcott will buy the U.S. rights to a treatment for overactive bladder for $400 million, the company said Friday.

 

The drug maker announced that it would terminate its co-promotion agreement with Novartis concerning the drug Enablex (darifenacin) and purchase the rights to sell it in the United States. It may be required to make additional milestone payments of up to $20 million to Novartis.

 

 

September 21, 2010

A U.S. District Court has blocked Canadian generic drug maker Apotex from selling generic versions...

PITTSBURGH A U.S. District Court has blocked Canadian generic drug maker Apotex from selling generic versions of an antidepressant drug.

 

Generic drug maker Mylan said Tuesday that it had obtained a temporary restraining order from the U.S. District Court for the District of New Jersey prohibiting Apotex from selling generic versions of the drug Paxil CR (paroxetine hydrochloride), an extended-release formulation of GlaxoSmithKline’s Paxil.

 

 

September 21, 2010

Merck is expanding its patient assistance program, the drug maker said Wednesday....

WHITEHOUSE STATION, N.J. Merck is expanding its patient assistance program, the drug maker said Wednesday.

September 12, 2010

Starting Monday, K-V Pharmaceutical will ship its first product since it withdrew several products in...

ST. LOUIS Starting Monday, K-V Pharmaceutical will ship its first product since it withdrew several products in 2008 and 2009 due to manufacturing problems, the drug maker said.

K-V said the Food and Drug Administration had given it approval to ship its Micro-K potassium chloride product following the completion of inspections of its manufacturing plant.

September 9, 2010

The federal government got a kick in the face Thursday as an appeals court ruled...

NEW YORK The federal government got a kick in the face Thursday as an appeals court ruled in favor of patent litigation settlements between branded and generic drug companies.

September 9, 2010

Efforts by two generic drug makers to market a generic version of a drug for...

NEW YORK Efforts by two generic drug makers to market a generic version of a drug for multiple sclerosis hit an obstacle this week in a U.S. District Court.

 

The U.S. District Court for the Southern District of New York denied a motion for summary judgment filed by Sandoz and Momenta Pharmaceuticals that patents covering Teva Pharmaceutical Industries’ drug Copaxone (glatiramer acetate) are invalid due to indefiniteness.

 

 

September 9, 2010

This week’s decision by the U.S. Second Circuit Court of Appeals could make political efforts...

WHAT IT MEANS AND WHY IT'S IMPORTANT This week’s decision by the U.S. Second Circuit Court of Appeals could make political efforts to ban generic-branded patent settlements a lot more difficult.

(THE NEWS: Appeals court upholds decision to OK 'pay-for-delay' deals. For the full story, click here)

September 8, 2010

Hi-Tech Pharmacal had $40.4 million in sales during its fiscal first quarter ended July 31,...

AMITYVILLE, N.Y. Hi-Tech Pharmacal had $40.4 million in sales during its fiscal first quarter ended July 31, the generic drug maker said Thursday. The numbers amounted to a decrease of $3 million from the same period in 2009.

 

September 7, 2010

The generics division of Pfizer will sell an authorized generic version of a drug used...

PEAPACK, N.J. The generics division of Pfizer will sell an authorized generic version of a drug used to treat dementia.

 

Greenstone said Wednesday that it had agreed with Eisai to launch donepezil hydrochloride tablets, an authorized generic of Aricept. The drug is used to treat dementia related to Alzheimer’s disease. Eisai makes the drug under a partnership with Pfizer.

 

 

September 7, 2010

Swiss drug maker Lonza will help British drug maker GlaxoSmithKline manufacture five biotech drugs in...

LONDON Swiss drug maker Lonza will help British drug maker GlaxoSmithKline manufacture five biotech drugs in early- and mid-stage clinical trials, the two companies said Wednesday.

 

Lonza will manufacture clinical trial batches of the drugs, all monoclonal antibodies in phase-1 and phase-2 testing, and provide additional access to manufacturing capacity so GSK can fulfill future demands. The two companies said other details of the agreement remain confidential.

 

 

September 7, 2010

The Food and Drug Administration has approved a generic oral contraceptive made by Watson Pharmaceuticals,...

MORRISTOWN, N.J. The Food and Drug Administration has approved a generic oral contraceptive made by Watson Pharmaceuticals, the drug maker said Tuesday.

 

Watson announced the FDA’s approval of Zarah (drospirenone and ethinyl estradiol tablets) in the 3 mg/0.03 mg strength. The drug is a generic version of Bayer’s Yasmin.

 

 

September 6, 2010

The generics subsidiary of Pfizer is launching a new business focused on authorized generics....

PEAPACK, N.J. The generics subsidiary of Pfizer is launching a new business focused on authorized generics.

 

Greenstone announced Tuesday the launch of the Authorized Generics Alliance, which it said would combine its business model and 17 years of experience in the generics market with the expertise of other drug makers to market authorized generics in the United States under the Greenstone label.

 

 

September 6, 2010

GlaxoSmithKline Consumer Healthcare on Tuesday named Stacy Wallace to the newly created role of VP...

PITTSBURGH GlaxoSmithKline Consumer Healthcare on Tuesday named Stacy Wallace to the newly created role of VP customer marketing and 360° Insights.

Under Wallace’s direction, the customer marketing and 360° Insights team will continue the development and execution of category visions and strategies in the area of health and wellness and in the creation of insight-led innovative and fully evaluated shopper marketing programs, the company stated.

September 6, 2010

Generic drug maker Watson Pharmaceuticals has applied for Food and Drug Administration approval for a...

MORRISTOWN, N.J. Generic drug maker Watson Pharmaceuticals has applied for Food and Drug Administration approval for a version of a drug used to treat eye diseases, Watson said Tuesday.

September 2, 2010

Pfizer is pulling out of a development deal for a potential brain cancer drug, saying...

NEEDHAM, Mass. Pfizer is pulling out of a development deal for a potential brain cancer drug, saying it is not a strategic priority, according to the drug's developer Celldex Therapeutics.

Celldex said it will regain full worldwide rights to develop and sell rindopepimut from Pfizer. The drug candidate also is called CDX-110. In May, the company reported positive results form a midstage study on the drug.

 

Celldex will regain rights to the drug candidate on Nov. 1.

 

September 1, 2010

Teva Pharmaceuticals has launched a generic treatment for epileptic seizures....

NORTH WALES, Pa. Teva Pharmaceuticals has launched a generic treatment for epileptic seizures.

 

The world’s largest generic drug maker announced Wednesday the launch of diazepam rectal gel, a generic version of Valeant Pharmaceuticals’ Diastat AcuDial. The drug is administered via rectal syringe and is available in 2.5-mg, 10-mg and 20-mg strengths.

 

 

August 31, 2010

Eli Lilly's method-of-use patents for its osteoporosis drug were declared valid by a federal court...

August 30, 2010

The Food and Drug Administration has pushed back its review date for a drug made...

LONDON The Food and Drug Administration has pushed back its review date for a drug made by GlaxoSmithKline and Valeant Pharmaceuticals.

The FDA has not yet completed the review of the new drug application for ezogabine, a drug designed to treat epileptic adults with partial onset seizures, after a formal risk evaluation and mitigation strategy was submitted to the agency from GSK and Valeant, per its request.

The FDA is expected to review the application by Nov. 30.

August 30, 2010

After Sanofi-Aventis sent Genzyme a second proposal letter to acquire the drug maker on Monday,...

CAMBRIDGE, Mass. After Sanofi-Aventis sent Genzyme a second proposal letter to acquire the drug maker on Monday, Genzyme said "the identical offer ... fails to establish a basis for engagement by the Genzyme board."

Sanofi-Aventis offered to acquire Genzyme for $69 per share in cash on two occasions. Prior to Monday's duplicate offer, the first offer was sent to Genzyme on July 29. The drug maker rejected the offer two weeks later.

August 30, 2010

The U.S. drug market will present opportunities as well as uncertainties over the next decade,...

SAN DIEGO The U.S. drug market will present opportunities as well as uncertainties over the next decade, according to remarks made by IMS Health VP industry relations Doug Long at the National Association of Chain Drug Stores’ 2010 Pharmacy and Technology Conference held here on Monday.

 

August 30, 2010

A generic drug maker has filed an abbreviated new drug application for its version of...

FOSTER CITY, Calif. A generic drug maker has filed an abbreviated new drug application for its version of a Gilead Sciences drug.

FOSTER CITY, Calif. A generic drug maker has filed an abbreviated new drug application for its version of a Gilead Sciences drug.

August 29, 2010

Jeffrey Bailey has been appointed as King Pharmaceuticals' chief commercial officer, leading all sales, marketing,...

BRISTOL, Tenn. Jeffrey Bailey has been appointed as King Pharmaceuticals' chief commercial officer, leading all sales, marketing, managed care, sales operations and business analytics for the drug maker.

BRISTOL, Tenn. Jeffrey Bailey has been appointed as King Pharmaceuticals' chief commercial officer, leading all sales, marketing, managed care, sales operations and business analytics for the drug maker.

August 29, 2010

Sanofi-Aventis is looking to acquire Genzyme with a nonbinding proposal valued at approximately $18.5 billion....

August 29, 2010

A drug maker and a consumer packaged goods company will co-promote a newly approved insomnia...

SAN DIEGO A drug maker and a consumer packaged goods company will co-promote a newly approved insomnia treatment.

Somaxon Pharmaceuticals and Procter & Gamble announced their co-promotion agreement for Silenor, in which Somaxon's promotion of the drug will target physicans, while P&G will promote Silenor to targeted pharmacies.